SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
XGN

Exagen Inc. (NASDAQ:XGN)

US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
$3.61-$0.19 (-5.00%)
 
Market cap
$92.1M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 19, 2019
Website
Market Cap$92.10M-52.3%
Revenue (ttm)$72.30M+13.7%
Net Income-$18.17M+4.6%
EPS-$0.76+17.4%
Shares Out25.51M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume508,828
Open$3.74
Previous Close$3.80
Day's Range$3.49 - $3.86
52-Week Range$2.59 - $9.22
Beta2.24
AnalystsBuy
Price Target$9.50(+163.16%)
Earnings DateMar 9, 2027

About XGN

Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.

Address
1261 Liberty Way, Vista, CA, 92081, US
Market Cap
92 million
Employees
216
Industrial Classification
Medical - Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.71M
Bought
$568.66K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy0 Hold0 SellAvg target $10.00 (+163.2%)

3 firms rating XGN in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From XGN’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.00%
5 Days
-10.86%
1 Month
-51.74%
6 Months
-15.26%
1 Year
-52.25%

$XGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in XGN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by XGN's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

XGN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

XGN Revenue by Segment

$18.42MTotal
Commercial$9.73M52.85%
Government$4.91M26.63%
Client direct bill$3.66M19.88%
Other$117.00K0.64%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New XGN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to XGN from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in XGN

VTIVanguard Morningstar Total Stock Market ETF$2.81M
VXFVanguard Extended Market ETF$1.64M
IWCiShares Micro-Cap ETF$151.13K
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF$90.00K
QQQSInvesco NASDAQ Future Gen 200 ETF$62.10K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from XGN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Q3 earnings beat revenue estimates with record revenue and 14 straight ASP gains, though company posted a net loss in the quarter.

Recent Insider Activity

Buys
4
Sells
9
Buy Value
$568.66K
Distinct Buyers
1

Insider Score Trend Over Time

+0.0 since Sep 3
0255075100Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 38.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 3Sep 18Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

QQQSInvesco NASDAQ Future Gen 200 ETF0.39%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.09%

Weight is the stock’s share of each fund’s holdings.